FastMarket.news

Apple Challenges EU's Digital Markets Act in New Appeal

Published 1 days agoAAPL
Apple Challenges EU's Digital Markets Act in New Appeal

Apple has filed an appeal challenging the European Commission's interpretation of the interoperability requirements under the Digital Markets Act (DMA). The act mandates tech giants like Apple to open up certain features and information, such as WiFi pairing and system notifications, to third-party developers and non-Apple devices. These provisions aim to promote competition and improve user access to app functionalities.


The Cupertino-based company has raised concerns that complying with these requirements would force it to disclose its intellectual property, potentially compromising user privacy and the seamless experience of its ecosystem. Apple has expressed that these regulations are not only cost-prohibitive but also pose a threat to innovation. A spokesperson from the company stated, "The EU's interoperability requirements threaten that foundation, while creating a process that is unreasonable, costly, and stifles innovation."


This latest move by Apple comes amidst broader efforts by the European Union to reign in the dominance of major technology firms. While Apple contests the DMA rules, other tech companies reliant on Apple's App Store see these regulations as a means to ensure fair competition and a chance to enhance their offerings. This legal battle underscores the ongoing tension between big tech and regulatory bodies aiming to enforce stricter competition laws.

Share this article

Recent Articles

Pinterest's Stock Climbs as Analysts Raise Price Targets

Pinterest's Stock Climbs as Analysts Raise Price Targets

3 minutes agoPINS

As of June 3, 2025, Pinterest Inc.'s stock price rose to $31.91 per share, marking a 2.59% increase from its previous close. This uptick comes amid positive sentiment from financial analysts, coupled with the company's latest strong performances and strategic advancements. J.P. Morgan recently revised its price target for Pinterest from $35 to $42, maintaining a Neutral rating. This revision follows a demonstration of robust financial health by Pinterest, including a 17.7% growth in revenue year-on-year and a gross profit margin of 78.9%. Additionally, the introduction of Pinterest's Performance+ platform is noted for improving advertiser returns through decreased costs and simplified campaign management, despite some challenges in certain advertising sectors like food and beverage. Pinterest's initiatives in AI-driven monetization and shoppable ads are being credited for driving growth expectations. For instance, BofA Securities has increased its price target to $46, referencing the company's strong execution with advanced AI models and enhanced user engagement. With these strategic developments and financial strides, Pinterest continues to capture the interest of financial analysts, further buoying its stock price.

Joby Aviation's Stock Gains Momentum with Saudi Partnership

Joby Aviation's Stock Gains Momentum with Saudi Partnership

18 minutes agoJOBY

Joby Aviation is making headlines following its recent announcement of a strategic partnership with Mukamalah Aviation, a subsidiary of Saudi Aramco. The partnership, formalized through a Memorandum of Understanding on May 21, 2024, will allow Joby to introduce its electric vertical takeoff and landing (eVTOL) aircraft in Saudi Arabia. This move is expected to accelerate Joby's market presence through direct sales to Mukamalah, which manages a vast fleet across the Kingdom. Canaccord Genuity is optimistic about Joby's prospects, maintaining a 'Buy' rating on the stock and setting a price target of $11.00, according to investing.com. The firm believes the partnership could lead to higher profit margins through international sales agreements and create recurring revenue opportunities in training and maintenance services. The collaboration is seen as a pivotal step for Joby's international expansion, resonating well with Saudi Arabia's Vision 2030 sustainability goals. The partnership not only reflects Joby Aviation's commitment to sustainable transport solutions but also highlights its strategic direction. As of June 3, 2025, Joby's stock price is $7.50, showing a slight dip of 4.09% from the previous close.

RTX Lands $1.31 Billion Navy Contract for F-35 Jets

RTX Lands $1.31 Billion Navy Contract for F-35 Jets

33 minutes agoRTX

RTX Corporation has secured a substantial $1.31 billion contract modification from the U.S. Navy to bolster the F135 propulsion system for the F-35 Lightning II aircraft. This significant contract is scheduled for completion by November 2025, reflecting a robust commitment to maintaining the technical excellence and readiness of the jet's engines, according to Nasdaq. The contract encompasses a comprehensive scope of work, including depot-level maintenance, repair, sustainment support, and engineering support for all operational F135 propulsion systems. This includes ongoing program management and procurement of spare parts. The agreement spans support for F-35 aircraft operated by the U.S. Air Force, Marine Corps, Navy, along with Foreign Military Sales customers and various international defense partners. Crucial work related to this contract will be carried out primarily in East Hartford, Connecticut, Oklahoma City, Oklahoma, and Indianapolis, Indiana. This development bolsters RTX's pivotal role in ensuring the F-35’s operational readiness and reliability, essential for U.S. military operations and allied forces worldwide.

Merck & Co. Eyes $3 Billion Acquisition of MoonLake Immunotherapeutics

Merck & Co. Eyes $3 Billion Acquisition of MoonLake Immunotherapeutics

48 minutes agoMRK

Merck & Co. is actively pursuing its acquisition strategy by engaging in talks to purchase Swiss biotech firm MoonLake Immunotherapeutics for over $3 billion. This move comes as Merck seeks to enhance its pharmaceutical pipeline, especially as the patent expiration of its blockbuster cancer drug, Keytruda, looms in 2028. Despite an initial nonbinding offer being rejected, interest remains high, particularly as MoonLake nears the release of late-stage clinical trial data for its drug, sonelokimab. The push to acquire MoonLake is part of Merck's broader strategy to sustain growth as it navigates challenges like the anticipated decline in revenue from its Gardasil vaccine in China and the impending loss of Keytruda's market exclusivity. Reuters highlights the significance of these moves as Merck explores mergers and acquisitions to mitigate these challenges, although the landscape for attractive deals is increasingly competitive. Merck is not only focusing on acquisitions but is also diversifying its portfolio through other avenues. Recent investments have targeted fields such as immunology and neuroscience, with notable acquisitions like EyeBio and Prometheus Biosciences in the past year. Additionally, the company is working on a subcutaneous version of Keytruda to extend its market reach post-patent expiry.